Poel D, Gootjes EC, Bakkerus L, et al. - This study was attempted to assess whether a specific microRNA profile as a predictive biomarker for systemic treatment in patients with metastatic colorectal cancer. Researchers prospectively collected samples from 132 patients who were treated with capecitabine or 5‐FU/LV with oxaliplatin ± bevacizumab. They conducted response evaluation according to RECIST 1.1 after three or four cycles, respectively. The logistic regression analysis was applied to test the combined predictive performance of selected variables. In this study, 81 fresh frozen tissue biopsies from metastases, and 93 serum samples were available from 132 patients. The results of this study indicated that the additive predictive value to clinical parameters of the tissue‐derived six miRNA profile for clinical advantage could not be confirmed in patients with mCRC treated with first‐line systemic therapy. It remained insufficient for clinical decision‐making, although miR‐92a‐3p and miR‐98‐5p serum levels improved the predictive value of clinical parameters.